 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] "There is no possibility that the merger with the OCI Group will fail," the Hanmi Group said in a post on the group's internal network. "This integration is a matter that has been carefully reviewed and decided by top executives of the Hanmi Group and OCI Group in anticipation of maximizing synergy in the business sector directly or indirectly."
"The final decision was made unanimously by the board of directors of each holding company," the Hanmi Group said. "There may be differences between the families of major shareholders, but this does not affect the big cause of integration."
"Even after the merger, the Hanmi Group will maintain its current system and focus more on developing R & D and new drugs," he added. "We have no plans to carry out artificial restructuring in the process."
In addition, the Hanmi Group once again stressed that the mission of all group companies will be maintained after the merger and that the integrated holding company will be operated under a two-member representative system.
In addition, Hanmi Group said it has not decided on future relations with Bukwang Pharm, an affiliate of OCI Group, and explained that it will closely examine business synergies in the future to strengthen its business competitiveness.
The Hanmi Group said it shared postings to correct unverified content and minimize confusion among executives and employees.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
